Stuart Goldstein

Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)

National Institute of Diabetes and Digestive and Kidney Diseases · R01

PI · $2.8M · Seattle Children's Hospital

Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury

Food and Drug Administration · R01

PI · $976.4K · Innovative Biotherapies, Inc.

Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in Children

Agency for Healthcare Research and Quality · R18

Contact PI · $1.5M · Cincinnati Childrens Hosp Med Ctr

Critical Translational Studies in Pediatric Nephrology

National Institute of Diabetes and Digestive and Kidney Diseases · P50

Project lead · $525.1K · Cincinnati Childrens Hosp Med Ctr

Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy

Principal investigator · Recruiting · Phase 2

Dana Fuhrman

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Principal investigator · Withdrawn

Children's Hospital Medical Center, Cincinnati

Registry for HF20 for Pediatric CRRT Under Emergency Use Authorization

Principal investigator · Completed

Children's Hospital Medical Center, Cincinnati

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKI

Principal investigator · Enrolling by invitation

Children's Hospital Medical Center, Cincinnati